Edwards Lifesciences (XTER:EWL) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:EWL Edwards Lifesciences Corp XTER:EWL
84 GF Score
Price €76.94
GF Value €82.44
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Edwards Lifesciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Edwards Lifesciences  (XTER:EWL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Edwards Lifesciences Cyclically Adjusted PS Ratio Related Terms


Edwards Lifesciences Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Cyclically Adjusted PS Ratio Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.97 12.35 10.94 10.36 9.70

Edwards Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.90 8.65 9.59 8.60 9.68

XTER:EWL vs BSX, DXCM, GEHC: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cyclically Adjusted PS Ratio falls into.


XTER:EWL
84GF Score
Edwards Lifesciences Corp XTER:EWL
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Edwards Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Edwards Lifesciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.592/333.9520*333.9520
=2.592

Current CPI (Jun. 2026) = 333.9520.

Edwards Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.013 241.428 1.401
201612 1.089 241.432 1.506
201703 1.277 243.801 1.749
201706 1.182 244.955 1.611
201709 1.079 246.819 1.460
201712 1.168 246.524 1.582
201803 1.128 249.554 1.509
201806 1.234 251.989 1.635
201809 1.219 252.439 1.613
201812 1.346 251.233 1.789
201903 1.374 254.202 1.805
201906 1.520 256.143 1.982
201909 1.546 256.759 2.011
201912 1.663 256.974 2.161
202003 1.613 258.115 2.087
202006 1.354 257.797 1.754
202009 1.548 260.280 1.986
202012 1.582 260.474 2.028
202103 1.600 264.877 2.017
202106 1.813 271.696 2.228
202109 1.759 274.310 2.141
202112 1.841 278.802 2.205
202203 1.899 287.504 2.206
202206 2.057 296.311 2.318
202209 2.097 296.808 2.359
202212 2.146 296.797 2.415
202303 2.227 301.836 2.464
202306 1.950 305.109 2.134
202309 1.875 307.789 2.034
202312 1.941 306.746 2.113
202403 2.028 312.332 2.168
202406 2.105 314.175 2.238
202409 2.064 315.301 2.186
202412 2.200 315.605 2.328
202503 2.284 319.799 2.385
202506 2.299 322.561 2.380
202509 2.269 324.800 2.333
202512 2.318 324.054 2.389
202603 2.427 330.213 2.454
202606 2.592 333.952 2.592

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Edwards Lifesciences (XTER:EWL) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €76.94 is trading 6.7% below its estimated GF Value™ of €82.44. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for XTER:EWL:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €82.44 vs. price of €76.94 (6.7% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the XTER:EWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
84GF Score

Get the complete analysis for XTER:EWL

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.94
Price
€82.44
GF Value